TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01106833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus + calcineurin inhibitor + prednisone
Description: The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus + prednisone
Description: The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day.
Study: NCT02698124

Intervention type: DRUG
Intervention: Decitabine
Study: NCT04130516

Intervention type: DRUG
Group type: OTHER
Intervention: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
Description: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pembrolizumab - anti-PD-1 antibody
Description: pembrolizumab- anti-PD-1 antibody
Study: NCT02598492

Intervention type: OTHER
Intervention: arterial blood gas
Description: Just record clinical lab data
Study: NCT00587327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barusiban
Description: Solution for IV treatment. Bolus and infusion for 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Solution for IV administration. Bolus and infusion for 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for IV administration. Bolus and infusion for 4 hours.
Study: NCT01911403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Closure procedure by Manual compression

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-Seal
Description: Closure procedure by angio-Seal
Study: NCT00062309

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04638985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV+DTaP+MMR
Description: sIPV+DTaP+MMR at the age of 18 month old

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sIPV
Description: sIPV at the age of 18 month old

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: DTaP at the age of 18 month old
Study: NCT03722927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
Study: NCT02200718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroVax
Description: NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IFA Incomplete Freund's Adjuvant
Description: IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
Study: NCT04638985

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR
Description: MMR at the age of 18 month old
Study: NCT00927459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-040201
Description: Single dose IV infusion
Study: NCT04376138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCI intervention
Description: 30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: 30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
Study: NCT00660842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 6 IV day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2 IV day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 IV every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60mg/m2 IV every week
Study: NCT02985866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Use of CTR at home for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor Augmented Therapy
Description: Use of personal pump with study CGM \& glucometer at home for 3 months
Study: NCT00201084

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uncertainty reduction
Description: At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
Study: NCT03073148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tangible Boost
Description: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution.
Study: NCT03665610

Intervention type: DRUG
Intervention: ozanimod
Description: ozanimod
Study: NCT04106726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soolantra® Ivermectin cream 1%
Description: Apply topically to the face once daily for 84 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin cream 1%
Description: Apply topically to the face once daily for 84 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Ivermectin cream 1%
Description: Apply topically to the face once daily for 84 consecutive days.
Study: NCT01067781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat-Labile Enterotoxin of E. coli (LT)
Description: Travelers' Diarrhea Vaccine System

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat-Labile Enterotoxin of E. coli (LT)
Description: Travelers' Diarrhea Vaccine System

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Travelers' Diarrhea Vaccine System

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Travelers' Diarrhea Vaccine System
Study: NCT03757728

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haemorrhoidectomy operations
Description: for treatment of symptomatic 2 to 3 degree haemorrhoids

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haemorrhoidectomy operations
Description: for treatment of symptomatic 2 to 3 degree haemorrhoids

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haemorrhoidectomy operations
Description: for treatment of symptomatic 2 to 3 degree haemorrhoids
Study: NCT00927459

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02347878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: use aprepitant 1 hour before lumbar puncture and intrathecal treatment
Study: NCT04275466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: necrotic cavity lavage
Description: 1. At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~2. Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~3. 1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~4. The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is \>100 mL.~5. Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is \>38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure.
Study: NCT04222101

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: measure insulin, glucose and FGF21 levels in response to oral glucose challenge
Study: NCT02675387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2%Lidocaine
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
Study: NCT00109655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic adenovirus (serotype 5) - CG0070
Description: Intravesical administration of CG0070 (in suspension) directly into the bladder
Study: NCT03711565

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Nasal CPAP using a conventional ventilator
Description: The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
Study: NCT02675387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2%Lidocaine
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
Study: NCT01795430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT04119661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Max-i-Probe
Description: Using Max-i-Probe as endodontic needle during syringe irrigation
Study: NCT01795430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo WB-MRI-guided IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study: NCT03711565

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Nasal CPAP
Description: High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
Study: NCT01795430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous peripheral blood stem cell or bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Undergo autologous bone marrow transplant
Study: NCT00879138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study: NCT03589079

Intervention type: GENETIC
Intervention: Sanger and/or Next Generation Sequencing (NGS)
Description: NGS panel, whole exome / genome sequencing (WES/WGS)
Study: NCT01804920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-serine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02919800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: MOD-5014, a long-acting modified recombinant Factor VIIa

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MOD-5014 Placebo
Description: Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
Study: NCT00477230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ablation System
Description: Single ablation procedure with Endoscopic Ablation System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Anti-arrhythmic Drug (AAD) Therapy
Description: Medication as prescribed by physician.
Study: NCT00942890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES (EMPI 300PV stimulator) plus standard of care
Description: In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
Study: NCT03626155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Control
Description: Participants will be asked to sit quietly and read during a 50 minute control period
Study: NCT00476216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Arixtra with chemotherapy
Description: Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 \& 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy.
Study: NCT03971682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSYCHOPATHY.COMP program.
Description: The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual - TAU
Description: Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual - TAU
Description: Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
Study: NCT02753790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume \[PTV\] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy.
Study: NCT01384708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proflavine
Description: 1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
Study: NCT03195868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Realief Therapy
Description: Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
Study: NCT04274907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) Infusion
Study: NCT03502655

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: Intervention message (first phase)
Description: Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Comparator: Control message (first phase)
Description: Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: Intervention message (second phase)
Description: Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Comparator: Control message (second phase)
Description: Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
Study: NCT01579591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: 1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
Study: NCT04119661

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaviTip
Description: Using NaviTip as endodontic needle during syringe irrigation
Study: NCT04280172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural Competence Education
Description: Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mentoring Education
Description: Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
Study: NCT02714686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radio Mass Media Family Planning Campaign
Description: Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
Study: NCT01579591

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
Study: NCT00942890

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TMARP standard of care
Description: The usual care is 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
Study: NCT03711682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.